Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Barry D. Quart"'
Publikováno v:
Journal of Clinical Pharmacology
The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e651479fbd56b52b7d7d3b00667397
https://doi.org/10.1002/jcph.1124
https://doi.org/10.1002/jcph.1124
Publikováno v:
Drug Design, Development and Therapy
Introduction Fosaprepitant, an intravenous (IV) aprepitant prodrug for chemotherapy-induced nausea and vomiting prophylaxis, is associated with systemic and infusion-site reactions attributed in part to its surfactant, polysorbate 80. HTX-019 is an I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8bddb8009e2c95908b74abc2ce8a5e1
https://doi.org/10.2147/dddt.s155875
https://doi.org/10.2147/dddt.s155875
Autor:
Michael Lauw, Thomas Ottoboni, Kimberly Manhard, Barry D. Quart, Neil J. Clendeninn, Matt Cravets, Mary Rose Keller
Publikováno v:
Future oncology (London, England). 15(8)
Aim: HTX-019 (CINVANTI® [aprepitant injectable emulsion]) is a neurokinin 1 receptor antagonist approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 is free of polysorbate 80 and other synthetic surfacta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320ce5d8400f647ab1297a4dc601e883
https://pubmed.ncbi.nlm.nih.gov/32631101
https://pubmed.ncbi.nlm.nih.gov/32631101
Autor:
Kimberly Manhard, Michael Lauw, Mary Rose Keller, Neil J. Clendeninn, Barry D. Quart, Tom Ottoboni, Matt Cravets
Publikováno v:
Future oncology (London, England). 14(27)
Aim: Evaluate safety of HTX-019, a novel polysorbate 80– and synthetic surfactant-free intravenous formulation of neurokinin 1 receptor antagonist aprepitant for chemotherapy-induced nausea and vomiting. Methods: Two open-label, randomized, two-way
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9b5973984e314efed0fdfb9df1482e1
https://pubmed.ncbi.nlm.nih.gov/29873529
https://pubmed.ncbi.nlm.nih.gov/29873529
Autor:
Colin Edward Rowlings, Vijay Hingorani, Kimberly Manhard, C. Storgard, Zancong Shen, Brad Kerr, Li-Tain Yeh, Barry D. Quart
Publikováno v:
Drug Design, Development and Therapy
Zancong Shen, Colin Rowlings, Brad Kerr, Vijay Hingorani, Kimberly Manhard, Barry Quart, Li-Tain Yeh, Chris Storgard Ardea Biosciences, Inc. (a member of the AstraZeneca group), San Diego, CA, USA Abstract: Lesinurad is a selective uric acid reabsorp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc99c7830ed003b252867a2a1d299df
http://europepmc.org/articles/PMC4494180
http://europepmc.org/articles/PMC4494180
Autor:
Barry D. Quart, Jean-Luc Girardet
Publikováno v:
2017 Medicinal Chemistry Reviews ISBN: 9780996293242
2017 Medicinal Chemistry Reviews
2017 Medicinal Chemistry Reviews
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6622e29a01d121628f74b4dc99dd9954
https://doi.org/10.29200/acsmedchemrev-v52.ch25
https://doi.org/10.29200/acsmedchemrev-v52.ch25
Autor:
Roy Fleischmann, Bradley Kerr, Matt Suster, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Kimberly Manhard, Elizabeth Polvent, Barry D. Quart, Scott Baumgartner, Vijay Hingorani
Publikováno v:
Rheumatology. 53:2167-2174
Objective. The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1c255ca16bb15e121b3ae4a165ac2d
https://doi.org/10.1093/rheumatology/ket487
https://doi.org/10.1093/rheumatology/ket487
Autor:
David T. Hagerty, Payal Nanavati, Philip K. Tan, Li-Tain Yeh, Barry D. Quart, Jean-Luc Girardet, Kimberly Manhard, Sha Liu, Robert Terkeltaub, Jeffrey N. Miner, Cory Iverson, David Hyndman, Zancong Shen
Publikováno v:
Arthritis Research & Therapy
Arthritis research & therapy, vol 18, iss 1
Arthritis research & therapy, vol 18, iss 1
Background Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9b4abb86e3a95270b00e9d402aec30
https://pubmed.ncbi.nlm.nih.gov/27733209
https://pubmed.ncbi.nlm.nih.gov/27733209
Autor:
Gary Larson, Todd Vo, Robert Hamatake, Jeffrey N. Miner, Barry D. Quart, Chon Lai, Cory Iverson, Paul Weingarten, Andreas Maderna, Claudia Dadson, Jean-Michel Vernier, Li-Tain Yeh, Todd Appleby
Publikováno v:
Cancer Research. 69:6839-6847
The RAS-RAF-mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK pathway provides numerous opportunities for targeted oncology therapeutics. In particular, the MEK enzyme is attractive due to high selectivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b650cc566d532b2088600c88610c6ff
https://doi.org/10.1158/0008-5472.can-09-0679
https://doi.org/10.1158/0008-5472.can-09-0679
Publikováno v:
Drug Information Journal. 34:617-629
Statistical methods developed for survival analysis (time to event) were applied to treatments which are potent viral load suppressers in HIV-infected subjects. The methodology was applied to HIV-RNA levels obtained from the clinical study AG1343-511
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcaf32f4bf034c8654b1065c50ab856c
https://doi.org/10.1177/009286150003400230
https://doi.org/10.1177/009286150003400230